Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 6/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471807 | 0.85 | OPRM1 (0.51) | CAPN1GRB2OPRM1TACR1BDKRB2 | |
| SCHEMBL29590494 | 0.84 | OPRM1 (0.51) | GRB2OPRM1BDKRB2 | |
| SCHEMBL30658587 | 0.84 | F2 (0.46) | GRB2OPRM1NPY1RNPY2RNPY4R | |
| SCHEMBL29360886 | 0.84 | GRB2 (0.49) | CAPN1GRB2OPRM1CXCL8TACR1 | |
| SCHEMBL29630459 | 0.84 | OPRM1 (0.53) | OPRM1BDKRB2 | |
| SCHEMBL30844274 | 0.84 | F2 (0.51) | GRB2OPRM1TACR1 | |
| SCHEMBL30689897 | 0.83 | CXCR4 (0.48) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31126292 | 0.83 | CAPN1 (0.43) | CAPN1CXCL8 | |
| SCHEMBL31126285 | 0.83 | BACE1 (0.43) | CAPN1GRB2OPRM1 | |
| SCHEMBL29415462 | 0.83 | F2 (0.47) | GRB2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795436-B2 | Derivation of hepatic stem cells and mature liver cell types and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-10-24 | — | — | US | claimed |
| CN-108431209-B | Derived and mature hepatocyte types of liver stem cells and uses thereof | 新加坡科技研究局 | 2023-02-10 | — | — | CN | claimed |
| CN-114207111-B | Method for producing skin-derived multipotent precursor cells | 花王株式会社 | 2025-05-30 | — | — | CN | disclosed |
| CN-119968461-A | Methods for differentiating endothelial cells | 朗格生物技术公共公益股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119968458-A | Methods for differentiating stromal cells or pericytes | 朗格生物技术公共公益股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025091318-A1 | IMPROVED PRODUCTION OF INDUCED MIDBRAIN DOPAMINERGIC PROGENITOR CELLS FROM PLURIPOTENT STEM CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-05-08 | — | — | WO | disclosed |
| CN-119948152-A | Methods and compositions for inducing hematopoietic cell differentiation | 菲特治疗公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250136934-A1 | PRODUCTION OF INDUCED MIDBRAIN DOPAMINERGIC PROGENITOR CELLS FROM PLURIPOTENT STEM CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| CN-119585417-A | Methods for differentiating AT2 cells | 朗格生物技术公共公益股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-114164167-B | Cell culture platform for single cell sorting and enhanced IPSC reprogramming | 菲特治疗公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-118871570-A | Production of brown adipocytes from human pluripotent stem cells | 布里格姆妇女医院 | 2024-10-29 | — | — | CN | disclosed |
| CN-118829724-A | Method for inducing cell differentiation | 科济生物医药（上海）有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-11795436-B2 | Derivation of hepatic stem cells and mature liver cell types and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-10-24 | — | — | US | disclosed |
| CN-116121180-A | Media and methods for producing cardiomyocytes from pluripotent stem cells | 安徽中盛溯源生物科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-108431209-B | Derived and mature hepatocyte types of liver stem cells and uses thereof | 新加坡科技研究局 | 2023-02-10 | — | — | CN | disclosed |
| US-11525133-B2 | Chimeric proteins | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-12-13 | — | — | US | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220090054-A1 | CHIMERIC PROTEINS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-03-24 | — | — | US | disclosed |
| US-11279925-B2 | Chimeric proteins | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | CAPN1 2517/4885GRB2 3638/4885OPRM1 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.